Last reviewed · How we verify
Quadrivalent VLP Influenza Vaccine
A plant-based virus-like particle (VLP) vaccine that presents influenza surface antigens to stimulate immune responses against four influenza virus strains.
A plant-based virus-like particle (VLP) vaccine that presents influenza surface antigens to stimulate immune responses against four influenza virus strains. Used for Prevention of seasonal influenza in adults.
At a glance
| Generic name | Quadrivalent VLP Influenza Vaccine |
|---|---|
| Sponsor | Medicago |
| Drug class | Quadrivalent influenza vaccine |
| Target | Influenza hemagglutinin and neuraminidase antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine is produced using plant-based expression technology to generate virus-like particles that mimic the structure of influenza viruses without containing infectious genetic material. These VLPs display hemagglutinin and neuraminidase antigens from four influenza strains (two A subtypes and two B lineages), triggering both humoral and cellular immune responses to provide protection against seasonal influenza infection.
Approved indications
- Prevention of seasonal influenza in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults (PHASE3)
- Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults (PHASE3)
- Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older (PHASE1, PHASE2)
- Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly (PHASE3)
- Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults (PHASE1, PHASE2)
- Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults (PHASE2)
- Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults (PHASE2)
- Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadrivalent VLP Influenza Vaccine CI brief — competitive landscape report
- Quadrivalent VLP Influenza Vaccine updates RSS · CI watch RSS
- Medicago portfolio CI